Combining an oral opioid-receptor agonist and the antagonist naloxone: A smart drug design that removes some but not all adverse effects of the opioid analgesic

Editorial

. 2014 Apr 1;5(2):72-74.

doi: 10.1016/j.sjpain.2014.02.004.

Harald Breivik^{1

2

3}, Mads U Werner⁴

Affiliations

¹ Department of Pain Management and Research, Oslo, Norway.
² Department of Anaesthesioology, Oslo University Hospital, Oslo, Norway.
³ University of Oslo, Oslo, Norway.
⁴ Multidisciplinary Pain Center, Neuroscience Center, Copenhagen University Hospitals, Rigshospitalet, Copenhagen, Denmark.

Free article

Editorial

Harald Breivik et al. Scand J Pain. 2014.

Free article

. 2014 Apr 1;5(2):72-74.

doi: 10.1016/j.sjpain.2014.02.004.

Harald Breivik^{1

2

3}, Mads U Werner⁴

¹ Department of Pain Management and Research, Oslo, Norway.
² Department of Anaesthesioology, Oslo University Hospital, Oslo, Norway.
³ University of Oslo, Oslo, Norway.
⁴ Multidisciplinary Pain Center, Neuroscience Center, Copenhagen University Hospitals, Rigshospitalet, Copenhagen, Denmark.

No abstract available

Cited by

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.